Clinical Trials Browser

Not yet recruiting × Leukemia, Myelomonocytic, Chronic × Clear all

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT07468916 2026-03-13

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

Phase 2 Not yet recruiting

35 enrolled

MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Thrombocytosis, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT07113730 2025-08-15

The Kinetics Profiling of Immune Reconstitution and Clinical Outcomes

Not yet recruiting

300 enrolled

Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic

NCT06900088 2025-03-28

Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients

Phase 2 Not yet recruiting

20 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Clinical Trials

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

The Kinetics Profiling of Immune Reconstitution and Clinical Outcomes

Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients